Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 188,500 shares, effective April 1, 2026, under the company's 2022 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $15.12, equal to the last reported Nasdaq sale price on April 1, 2026.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – OLMA
On the day this news was published, OLMA gained 0.73%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OLMA was up 1.41% while key peers were mixed: ARVN and SAGE were down, whereas BCAX, ORKA, and VSTM were up. Momentum scanner only flagged one peer (ATYR), suggesting today’s setup looks more stock-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Preclinical data update | Positive | -3.3% | AACR preclinical posters for palazestrant and OP-3136 were announced. |
| Mar 16 | Earnings and funding | Positive | +9.6% | Q4/FY25 results with $218.5M raise and $505.4M cash disclosed. |
| Mar 03 | Inducement option grants | Neutral | +3.9% | Inducement options for 205,000 shares granted to new employees. |
| Feb 19 | Conference appearance | Neutral | +1.1% | Management participation in TD Cowen health care conference announced. |
| Feb 04 | Investor conferences | Neutral | -5.0% | Participation in three February investor conferences outlined. |
News flow has produced mixed reactions: earnings and some operational updates saw positive moves, while conference and data-presentation announcements have occasionally coincided with pullbacks.
Over the past few months, Olema has advanced its breast cancer pipeline and strengthened its balance sheet. Earnings on Mar 16, 2026 highlighted a follow-on raise of $218.5 million and cash of $505.4 million, with shares rising 9.59%. Earlier and subsequent news covered conference participation, preclinical AACR data, and prior inducement grants with varied price reactions, framing today’s grants as part of ongoing corporate and R&D activity rather than a new clinical or financial inflection point.
Market Pulse Summary
This announcement details inducement stock options for four new employees covering 188,500 shares at an exercise price of $15.12, with a four-year vesting schedule and a 10-year term. Such grants are standard for growing biopharmaceutical companies and governed here by Nasdaq Listing Rule 5635(c)(4). In context of Olema’s recent financing, advancing Phase 3 programs, and documented insider sales, investors may watch future equity awards and ownership changes alongside key clinical milestones.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
exercise price financial
inducement plan financial
AI-generated analysis. Not financial advice.
SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock, effective as of April 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
